Skip to main content

Innovative Glycan-based analysis for Cancer diagnostics

Project description

A sensitive diagnostic for prostate cancer

The prostate-specific antigen (PSA) is currently used as a biomarker for prostate cancer. However, PSA tests lack diagnostic accuracy as they have a high false positive rate, leading to wrong treatments and unnecessary prostate biopsies. To address this problem, scientists of the EU-funded GlyCan project have developed an innovative diagnostic assay capable of detecting glycan changes on the PSA protein. The test has 86 % accuracy and can discriminate between the healthy and the abnormal form of the protein. The GlyCan approach offers a reliable method for analysing complex biomolecules, and its use can also extend to other diseases.

Call for proposal

See other projects for this call


Dubravska Cesta 9
845 38 Bratislava
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000